Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Hepatitis B virus (HBV) infects 290 million people worldwide. Oxford Nanopore Technology sequencing platforms provide potential for sequencing the whole HBV genome in a single read, facilitating improved insights into virus epidemiology, diversity, and pathogenesis.

Dr Anna McNaughton and fellow researchers from the Translational Gastroenterology Unit have developed laboratory and bioinformatic methods enabling accurate HBV sequencing using the Nanopore platform

Read the full article